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Abstract
Objective: To test the hypothesis that among cognitively healthy individuals, distinct
groups exist in terms of amyloid and phosphorylated-tau accumulation rates; that if
rapid accumulator groups exist, their membership can be predicted by Alzheimer’s dis-
ease (AD) risk factors, and that time points of significant increase in AD protein accu-
mulation will be evident.
Methods: The analysis reports data from 263 individuals from the BIOCARD and 184
individuals from theBaltimore Longitudinal Study ofAgingwith repeated cerebrospinal
fluid (CSF) and positron emission tomography (PET) sampling, respectively. We used
latent class mixed-effect models to identify distinct classes of amyloid (CSF and PET)
and p-Tau (CSF) accumulation rates and generalized additive modeling to investigate
non-linear changes to AD biomarkers.
Results: For both amyloid and p-Tau latent class models we confirmed the existence of
two separate classes: accumulators and non-accumulators. The accumulator and non-
accumulator groups differed significantly in terms of baseline AD protein levels and
slope of change. APOE 𝜀4 carrier status and episodic memory predicted amyloid class
membership. Non-linear models revealed time points of significant increase in the rate
of amyloid and p-Tau accumulationwherebyAPOE 𝜀4 carrier status associatedwith ear-
lier age at onset of rapid accumulation.
Conclusions: The current analysis demonstrates the existence of distinct classes of
amyloid and p-Tau accumulators. Predictors of class membership were identified but
the overall accuracy of the models was modest, highlighting the need for additional
biomarkers that are sensitive to early disease phenotypes.
K EYWORD S
amyloid, CSF, emerging Alzheimer’s disease pathology, positron emission tomography, phosphory-
lated tau
1 BACKGROUND
Evidence of abnormal amyloid burden (“amyloid positivity”) is now a
standard inclusion criterion for clinical trials of disease modification
agents in pre-dementia Alzheimer’s disease (AD).1,2 However, recent
evidence has challenged the notion thatwidespread amyloid pathology
is required before downstream neurodegenerative effects are evident
and argue for the existence of clinically relevant “emerging amyloid
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pathology.”3 Specifically, cognitively healthy individuals classed as
“amyloid negative” but with evidence for steep slope of amyloid
accumulation have increased frontoparietal atrophy rates,4 memory
decline,5 and tau accumulation.6 In addition, evidence exists for tau
emerging independently and earlier than amyloid7 and thus identifying
individuals on an aggressive tau accumulation trajectory in conjunction
with amyloid or on its own8 is of interest. Furthermore, the rate of
increase in AD biomarkers does not appear to follow a linear course
but rather features points of acute acceleration.9,10 Taken together
these data argue that an intervention’s impact is likely to be greatest
if delivered (1) to individuals on aggressive trajectory of AD protein
accumulation and (2) in temporal proximity to time points of rapid AD
protein burden acceleration.
In this analysiswe sought to identifywhether subgroups of rapidAD
protein accumulators exist among initially cognitively healthy individu-
als in two large longitudinal cohorts sampling cerebrospinal fluid (CSF)
and positron emission tomography (PET), respectively. We hypothe-
sized that if rapid accumulator groups exist, their membership can be
predicted byAD risk factors and that time points of significant increase
in AD protein accumulation will be evident.
2 METHODS
2.1 Study design and participants
The study reports data from the Biomarkers of Cognitive Decline
Among Normal Individuals (BIOCARD) and Baltimore Longitudinal
Study of Aging (BLSA) studies. BIOCARD was established in 1995
by the National Institutes of Health (NIH). The goal was to evaluate
risk factors for progression to AD among cognitively healthy individ-
uals. The study was stopped in 2005 and re-started at Johns Hop-
kins University (JHU) in 2009. Between 1995 and 2005, participants
were assessed cognitively and clinically annually with CSF, blood sam-
pling, and magnetic resonance imaging (MRI) collection every 2 years.
Since 2009, participants have been seen annually for clinical, cognitive
assessments and to provide blood samples. In 2015, bi-annual collec-
tion of MRI and CSF was re-started. Exclusion criteria were (1) cogni-
tive impairment as determinedby cognitive testing; (2) significantmed-
ical or neurological conditions (eg, atrial fibrillation, epilepsy, multiple
sclerosis); and (3) chronic psychiatric disorders (eg, schizophrenia, drug
or alcohol abuse/dependence).
The BLSA sample included participants from its neuroimaging
sub-study, which was initiated in 1994 and included annual MRI
evaluations.11 At enrollment, participants were free of central nervous
system (CNS) disease (dementia, stroke, bipolar illness, epilepsy), and
severe cardiac (myocardial infarction, coronary artery disease requir-
ing angioplasty, or coronary artery bypass surgery), pulmonary, or
metastatic disease. Since 2003, participants were assessed every 1 (if
older than80years), 2 (ages60–79), or 4 years (younger than60years).
Beginning in 2005, participants were imaged with 11C-Pittsburgh
compound B (PiB) amyloid PET.
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using traditional (eg, PubMed) sources. The concept of
“emerging amyloid pathology” is gathering momentum,
and recent evidence of pathophysiological relevance of
rapid Alzheimer’s disease (AD) protein accumulation in
the absence of biomarker “positivity” is appropriately
cited.
2. Interpretation: Our findings demonstrate that repeated
AD protein sampling through cerebrospinal fluid (CSF)
and positron emission tomography (PET) in initially cogni-
tively healthy individuals allows the identification of dis-
tinct groups of accumulators and non-accumulators in
respect to both amyloid and p-Tau. In addition, critical
timepoints of significant escalation in accumulationoccur
and these are APOE4 dependent.
3. Future directions: Development of novel treatments
targeting AD pathology can be boosted by target-
ing pre-symptomatic individuals on an aggressive accu-
mulation trajectory. Prediction of accumulator group
membership was modest based on established AD risk
factors in this study, which emphasizes the need to
develop biomarkers specific to the preclinical stage of the
disease.
2.2 Participants
We focused on participants who had CSF (BIOCARD) or PET (BLSA)
testing. Included participants were aged >40 years and had Mini-
Mental State Examination (MMSE) ≥ 25 at first CSF or PET measure-
ment. This resulted in 588 CSF data points for 263 participants (BIO-
CARD) and 496 PET observations for 184 participants (BLSA); see
descriptives in Table 1.
2.3 Cognitive assessments
We selected two cognitive measures that were shared between the
two studies: the long delayed free recall variable of the California Ver-
bal Learning Test (CVLT) and total score of theMMSE.
2.4 Genetic analysis
APOE 𝜀4 status was determined using standard procedures12 or
TaqMan.13 We coded participants into two groups: those with and
without APOE 𝜀4 carriership.
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TABLE 1 Demographics, cognitive scores, and number of CSF andMRI individual data points per individual
BIOCARD BLSA
Variables Mean (SD) Range Mean (SD) Range
Age at baseline 58 (8.2) 42–64 79 (8.1) 55–95
Education 17 (2.4) 12–20 17 (2.3) 8–21
MMSE (first observation) 29.5 (0.8) 25–30 28.7 (1.2) 25–30
MMSE (last observation) 29.4 (1.03) 23–30 28.3 (1.5) 22–30
No. of CSF/PETmeasurements 2.2 (1.3) 1–6 2.6 (1.9) 1–9
MRImeasurements 2.0 (1.1) 1–5 2.3 (1.7) 1–9
Percentage (N= 263) Percentage (N= 184)
%Female (N) 59% (154) 48% (88)
%Caucasian N 97% (255) 78% (143)
% APOE 𝜀4 carriers (%) 36% (95) 30% (57)
APOE, apolipoprotein E gene; CSF, cerebrospinal fluid; MMSE,Mini-Mental State Examination;MRI, magnetic resonance imaging.
2.5 CSF analysis
CSFwas collected after anovernight fast into polypropylene tubes, and
A𝛽1-42 and p-Tau181 were measured on the Luminex platform using
the AlzBio3 kit (4D7A3 and AT270 monoclonal antibodies, respec-
tively). Each subject had all samples (run in triplicate) analyzed on the
same plate.14
2.6 MRI
For BIOCARD, baseline MRI scans were acquired at the NIH on a GE
1.5T scanner using a standard multimodal protocol. The baseline MRI
measures that were used as part of the biomarker composite score
were reconstructed from coronal spoiled gradient echo scans (repeti-
tion time [TR] = 24 ms, echo time [TE] = 2 ms, flip angle = 20◦, image
matrix = 256 × 256 mm, thickness/gap = 2.0/0.0 mm, 124 slices). The
mean time between the baseline MRI scan and the baseline cogni-
tive assessment was 8.6 days (standard deviation [SD] = 40.4, range
= 0-362). The volume of the hippocampus was obtained with a semi-
automated method, based on large deformation diffeomorphic met-
ric mapping techniques, which included adjustment for intracranial
volume.15
In the case of BLSA data, magnetization-prepared rapid gradient
echo (MPRAGE) images were acquired either on a 3 T Philips Achieva
scanner (TR= 6.8ms, TE= 3.2ms, flip angle= 8◦, imagematrix= 256×
256 mm, 170 slices, pixel size = 1 × 1 mm, slice thickness = 1.2 mm) or
a 1.5 T Philips Intera scanner (TR = 6.8 ms, TE = 3.3 ms, flip angle = 8◦,
image matrix = 256 × 256 mm, 124 slices, pixel size = 0.94 × 0.94 mm,
slice thickness = 1.5 mm), or spoiled gradient-recalled images were
acquiredona1.5TGESigna scanner (TR=35ms, TE=5ms, flip angle=
45◦, image matrix = 256 × 256 mm, 124 slices, pixel size = 0.94 × 0.94
mm, slice thickness = 1.5 mm). Anatomical labels and regional brain
volumes were obtained using MUlti-atlas region Segmentation using
Ensembles of registration algorithms and parameters16 with atlases
that have been harmonized to account for differences in scanners and
acquisition parameters.17 We corrected for intracranial volume esti-
mated at age 70 using a residual volume approach described earlier.18
Residual volumes were computed for each region and each scan as the
difference, in mm3, of the measured regional volume from the regional
volume that would be expected given the ICV of the individual.
2.7 PET analysis
Dynamic 11C-PiB PET studies (3D mode on GE Advance scanner)
started immediately after intravenous bolus injection of 555 MBq
(15mCi) of 11C-PiB.Dynamic imageswere reconstructed using filtered
back-projection with a ramp filter to yield 33 time frames over 70min-
utes (4 × 0.25, 8 × 0.5, 9 × 1, 2 × 3, and 10 × 5 minutes), with a spa-
tial resolution of approximately 4.5 mm full width at half maximum
(FWHM)at the center of the field of view (image matrix = 128 × 128,
35 slices, voxel size= 2 × 2 × 4.25mm).
Eachof the33 timeframeswas aligned to themeanof the first 2min-
utes to correct for motion using SPM’s Realign (https://www.fil.ion.ucl.
ac.uk/spm/software/spm12/).19 The average of the first 20 min-
utes of PET scans was rigidly registered onto the corresponding
inhomogeneity-corrected MPRAGE, and the anatomical label image
was transformed from MRI to PET space using FLIRT20 implemented
in FSL (https://fsl.fmrib.ox.ac.uk/fsl, version 5.0).21 Distribution volume
ratio (DVR) images were computed in PET native space using a simpli-
fied reference tissue model22 with cerebellar gray matter as the refer-
ence region.Mean cortical amyloid 𝛽 (A𝛽) burdenwas calculated as the
average of the DVR values in cingulate, frontal, parietal (including pre-
cuneus), lateral temporal, and lateral occipital cortical regions, exclud-
ing the sensorimotor strip.
2.8 Statistical analysis
We used latent class mixed-effect models23 to identify distinct classes
of individuals with similar longitudinal patterns of AD biomarker
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change (CSF Abeta-42 and p-Tau in BIOCARD; mean amyloid cortical
DVR in BLSA). The intercept of the model was centered on 40 years of
age for BIOCARD and 55 years for BLSA, adjusting it for the earliest
age at which AD proteins are sampled. The latent class mixed-effect
model uses a random-effect structure when estimating heterogeneity
between individuals’ growth curves, allowingestimatesof potential dif-
ferent classes of accumulators and probabilities of class membership.
We calculated the differences between the groups on the variables of
interest and combined this analysis with logistic regression to investi-
gate prediction of class membership. Where repeated measures were
available for the predictors (MMSE, episodic memory, hippocampal
volume) we used their average values over the study duration. The
class interpretation, together with the Akaike, Bayesian, and sample-
size adjusted Bayesian information criteria (AIC, BIC, and SABIC,
respectively), was used to compare models with different levels of
complexity.
To investigate the nonlinearity of change of AD-related CSF and
PET biomarkers and impact of hypothesized predictors we used gen-
eralized additive mixed-effect models (GAMs24). Mixed-effect models
allowus to account for time-related repeatedmeasures per participant
by including a random structure, that is, participants’ unique effects
in regression. In other words, our models take into account variability
in the baseline of amyloid and p-tau protein levels, as well as, speed
of accumulation when fitting the general age-related changes. We
estimated the age-related function of AD biomarkers and explored
the impact of APOE 𝜀4 status on these changes. We also investigated
periods of statistically significant changes in the slope of the non-
linear function25 taking into account APOE 𝜀4 using finite differences
method.26 The idea behind this method is to replace continuous
prediction of the model by the discrete points placed across variable
of interest (age—in this study). We then approximate derivatives
between each pair of points to obtain changes of dependent variable
(ie, CSF amyloid accumulation) across the independent predictor (ie,
age). Finally, we take into account uncertainty of prediction (lower and
upper 95% confidence interval [CI]) to infer whether this change is
statistically significant. All models, R code, as well as, main and supple-
mentary results are reported in onlinematerials https://osf.io/fcuyd/).
To estimate the clinical impact of being classed as an accumulator
or non-accumulator we usedmixed-effect Cox regression fitted on the
longitudinal observations in the BIOCARD data. In these models, we
investigated whether the likelihood of being diagnosed with cognitive
impairmentordementia changesdependentonmembership in amyloid
accumulator, p-Tau accumulator, or both or neither groups.
3 RESULTS
3.1 Latent class modeling: amyloid
We investigated the existence of distinct groups underlying the
pattern of amyloid (CSF and PET amyloid separately) and p-Tau (CSF)
accumulation by using latent class mixed-effect modeling. The model
included random intercept adjustments for participants, as well as
random slopes for influence of age. Results confirmed our hypoth-
esis that two separate groups of participants existed in the case of
amyloid for both CSF and PET: non-accumulators and accumulators
(Figure 1A and 1B; see Table 2 for demographics and clinical data).
With regard to the CSF amyloid levels, the group of non-accumulators
was characterized by significantly higher intercept and shallower
decline over time (see Table 3). In contrast, the accumulators tended to
have lower intercept and steeper accumulation of amyloid over time,
that is, reduction in CSF Abeta-42 levels (see Figure 1C). Classification
of participants into these two groups resulted in 197 participants
assigned to the non-accumulator group with an average probability of
0.81 and 66 participants assigned to the accumulator group with an
average probability of 0.89.
An identical pattern occurs in PET amyloid, where the accumula-
tor group was characterized by higher intercept and steeper increase
over time relative to the non-accumulator group. The classification of
the sample into two groups resulted in 144 people being classified as
non-accumulators, with an average probability of 0.99 and 40 people
being assigned to the accumulator group with average probability of
0.98. AIC, BIC, and SABIC model comparisons confirmed that a two-
group separation is the best fit for the CSF amyloid, PET amyloid, and
CSF taumodels (see supplementarymaterials for model comparisons).
3.2 Predicting amyloid latent class: CSF and PET
Next we tested whether prediction of the latent class of amyloid pro-
gression in CSF and PET can bemade using logistic regression with the
probit link function. In the case of CSF-derived amyloid, results show
that APOE 𝜀4 carriership increases the probability of belonging to the
accumulator group (Table 4). Episodic memory (long delayed recall of
theCVLT)was the only other significant predictorwhereby lower num-
bers of recalled words associated with higher likelihood of belonging
to the accumulator group. Years of education approached significance,
with higher education increasing the probability of belonging in the
non-accumulator group. The logisticmodel reached 0.77 accuracywith
0.08 sensitivity and 0.98 specificity at the 0.5 threshold, whereas the
area under the curve was 0.66.
The PET-derived amyloid model replicated the effect of APOE 𝜀4,
whereby carriers had an increased probability of belonging to the accu-
mulator group. Neither episodic memory, measured as delayed recall,
nor years of education was a statistically significant predictor in this
model. The logistic model reached 0.81 accuracy, with 0.171 sensitiv-
ity and 0.992 specificity at the 0.5 threshold, while the area under the
curve was 0.69.
3.3 Latent class modeling: p-Tau (CSF)
Similar to the amyloid analyses, the latent classmixed-effect regression
suggested the existence of two different groups of p-Tau accumulators
(Figure 1C; see cross-validation subchapter in supplementary mate-
rials). The validity of the latent class modeling was supported by AIC
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F IGURE 1 Alzheimer’s disease (AD) protein intercept and change over time for two distinct accumulation groups in the BIOCARD and BLSA
cohorts. Plots represent BIOCARD amyloid cerebrospinal fluid (CSF) concentration (A), positron emission tomography (PET) mean cDVR (B), and
BIOCARD tau CSF levels (C). Accumulator classes shown in dotted line; non-accumulators shown in solid line
TABLE 2 Demographics, cognitive scores, and number of CSF andMRI individual data points per individual for the two BLSA latent classes
(amyloid accumulators and non-accumulators) and the four latent classes in the BIOCARD study (amyloid accumulators, P-Tau accumulators,
amyloid and P-tau accumulators, and non-accumulators)
BLSA BIOCARD
Amyloid PET
accumulators
Amyloid PET
non-accumulators
Amyloid CSF
accumulators
p-Tau CSF
accumulators
Amyloid and
p-Tau CSF
accumulators
CSFNon-
accumulators
Variables Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age at baseline 79.2 (7.0) 75.2 (8.3) 58.6 (8.3) 58.1 (6.6) 64.1 (8.2) 58.6 (8.3)
Education 16.7 (2.3) 17.3 (2.2) 16.4 (2.7) 17.7 (1.4) 16.7 (2.6) 17.2 (2.3)
MMSE (first observation) 28.7 (1.0) 28.8 (1.3) 29.4 5 (1.1) 29.7 (0.5) 29.7 (0.5) 29.5 (0.8)
MMSE (last observation) 28.4 (1.4) 28.7 (1.4) 29.4 (1.3) 29.7 (0.5) 28.3 (2.3) 29.5 (0.7)
N of CSF/PET
measurements
3.2 (2.2) 2.6 (1.9) 2.0 1 (1.4) 3.6 (1.4) 2.7 (1.2) 2.2 (1.3)
MRImeasurements 3.2 (2.2) 2.6 (1.9) 1.9 (1.1) 3.1 (1.0) 2.5 (0.9) 1.9 (1.1)
Average follow-up years 1.55 (0.8) 1.83 (0.9) 1.89 (0.6) 1.88 (0.3) 1.73 (0.5) 2.07 (0.8)
Percentage
(N= 40)
Percentage
(N= 144)
Percentage
(N= 51)
Percentage
(N= 7)
Percentage
(N= 15)
Percentage
(N= 190)
%Female (N) 35% (14) 51% (74) 49% (25) 71%(5) 60% (9) 60% (115)
%Caucasian (N) 82% (33) 76% (110) 96% (49) 100% (7) 100% (15) 96% (184)
% APOE 𝜀4 carriers (N) 52% (21) 25% (36) 50% (26) 57% (4) 46% (7) 30% (58)
APOE, Apolipoprotein E gene; CSF, cerebrospinal fluid; MMSE,Mini-Mental State Examination;MRI, magnetic resonance imaging.
TABLE 3 Summary of the amyloid level intercept and change over time for amyloid accumulators and non-accumulators for CSF (BIOCARD)
and PET (BLSA)
BIOCARD (CSF Amyloid)
Accumulators (N= 66) Non-Accumulators (N= 197)
Intercept (SE) p Age (SE) p Intercept (SE) p Age (SE) p
Estimate 387.78 (41) .0000 −4.847 (1.47) .001 480.41 (15) .0000 −2.374 (0.81) .003
BLSA (PETAmyloid)
Accumulators (N= 40) Non-Accumulators (N= 144)
Intercept (SE) p Age (SE) p Intercept (SE) p Age (SE) p
Estimate 1.17 (0.029) .0000 0.0075 (0.001) .000 0.99 (0.01) .0000 0.0006 (0.0004) .167
and BIC comparisons. The p-Tau non-accumulators were characterized
by a lower baseline level as well as shallower increase over time
compared with the group of p-Tau accumulators (see Table 5 and Fig-
ure 1C). Classification of participants into these two groups resulted
in 241 participants being assigned to the non-accumulator group with
average probability of 0.96 and 22 participants to the accumulator
groupwith average probability of 0.85. None of the predictors of p-Tau
accumulator class reached statistical significance.
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TABLE 4 Summary of predictors of amyloid accumulator class membership for CSF and PET-derived amyloid levels (BIOCARD and BLSA
studies respectively)
BIOCARD
Coefficients Estimate Std. error z value Pr (>|z|)
Intercept 0.220 4.24 0.048 .961
APOE 𝜺4 carriership 0.531 0.20 2.623 .008
Sex (women) −0.164 0.20 −0.783 .433
Race (non-white) −0.413 0.68 −0.601 .547
Hippocampal volume (residuals) −0.0002 0.00041 −0.488 .625
Years of education −0.073 0.041 −1.759 .078
MMSE total score 0.049 0.142 0.350 .726
CVLT free recall (long) −0.071 0.034 −2.038 .041
BLSA
Intercept −0.85 3.13 −0.272 .785
APOE 𝜺4 carriership 0.714 0.24 2.964 .003
Sex (women) −0.36 0.25 −1.274 .202
Race (non-white) −0.26 0.29 −0.893 .371
Hippocampal volume −0.19 0.17 −1.088 .276
Years of education −0.07 0.049 −1.572 .115
MMSE total score 0.04 0.112 0.393 .696
CVLT free recall (long) −0.001 0.041 −0.024 .980
All predictors are based on averagedmeasurements per participant. Apolipoprotein E gene (APOE), California Verbal Learning Task (CVLT).
TABLE 5 Summary of the CSF p-Tau level intercept and decline over time for accumulators and non-accumulators
BIOCARD (CSF p-Tau)
Accumulators (N= 22) Non-accumulators (N= 241)
Intercept Est(SE) p Age p Intercept p Age p
Estimate 33.21 .0026 1.534 .000 27.45 .0000 0.333 .003
3.4 Amyloid and p-Tau subclasses: clinical impact
Classifying study participants into amyloid and p-Tau accumulators
allowed the generation of a 2 × 2 grouping in BIOCARD with the fol-
lowing groups: non-accumulators for both, amyloid accumulators only,
p-Tau accumulators only, and both amyloid and p-Tau accumulators.
Breakdown of dementia-related eventual clinical diagnoses at last
study visit for the four groups revealed that the group of amyloid and
p-Tau accumulator had a 23% prevalence of clinical diagnoses (demen-
tia, MCI, impaired non-MCI), whereas in the amyloid only group it was
11%. None of the participants in the p-Tau accumulator group had
a clinical diagnosis, whereas 4% in the non-accumulator group had
been diagnosed. Mixed-effect Cox-regression analysis, that included
adjustments of the intercept estimates for participants, revealed that
only the amyloid accumulator group was predictive of dementia-
related diagnosis (𝛽 = 1.22, exp(𝛽) = 3.39, SE = 0.63, z = 1.94, p = .05),
when controlling for age and APOE 𝜀4 status (see Cox regression in
supplementary materials). The lack of statistically significant effect
in the p-Tau accumulator group is probably due to the low number of
cases.
3.5 Non-linearmodel: age andAPOE 𝜺4
The age-related model revealed a non-linear rate of accumulation for
CSF- andPET-derivedamyloid (Figure2) acrossparticipants’ age. In the
case of CSF, the statistically significant decline occurred between the
ages of 57 and 77. Stratifying the data set in terms of APOE 𝜀4 showed
that non-carriers started declining significantly in their CSF amyloid
level after the ageof 58 (Figure2, upper left panel), whereas the change
started from the age of 53 in carriers and continued until the age of 90
(Figure 2, upper right panel). In the case of PET amyloid, we observed
an exponential increase in amyloid burden as individuals aged (see
Figure 2). Statistically significant increase started at the age of 68 and
continued throughout the lifetime. The function was modulated by
APOE 𝜀4, whereby carriers started to accumulate amyloid significantly
faster at the age of 60 (Figure 2, bottom right panel), whereas non-
carriers started increasing at the age of 69 (Figure 2, bottom left panel).
In the case of p-Tau, significant increases were observable between
the ages of 55 and 73 (Figure 3). Stratifying by APOE 𝜀4 revealed
that non-carriers started to show increases in CSF p-Tau approxi-
mately when they were 59-years-old (Figure 3, left panel). In contrast,
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F IGURE 2 Non-linear accumulation of AD biomarkers across participants’ age: CSF Abeta-42 (upper panels) and PET amyloid (bottom panels).
The red area of the curve indicates statistically significant periods of changes in the age-related function. The age-related changes aremodulated
by APOE 𝜀4 status. (See non-carriers (panels on the left) and carriers (panels on the right) presented separately)
F IGURE 3 Non-linear accumulation of CSF p-Tau across age in BIOCARD. The red area of the curve indicates statistically significant periods of
increases in the age-related function. The age-related changes aremodulated by APOE 𝜀4. Non-carriers (panels on the left) and carriers (panels on
the right) presented separately
APOE 𝜀4 carriers started to accumulate p-Tau at the age of 40 (Figure 3,
right panel) and the pattern of increase in this group remained linear
thereafter.
4 DISCUSSION
In this study, we sought to establish whether distinct subtypes of
AD biomarker progression exist. Analyses for both amyloid and
p-Tau yielded two classes for each—faster and slower AD protein
accumulators. Although we successfully identified predictors for class
membership, the overall accuracy of the models was modest. We also
explored the non-linear dynamics of amyloid and p-Tau concentrations’
relationship with age. We found that as predicted from previous
studies, amyloid concentrations remain largely static until themid-50s,
with evidence for rapid increase of accumulation thereafter. The rela-
tionship was similar for p-Tau, and we found that the age of significant
change was 57 for amyloid and 55 for p-tau. The non-linear rate of
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progressionwas influenced byAPOE 𝜀4 status, whereby having at least
one allele led to a sharp increase in AD protein burden at a younger
age.
The amyloid latent class result represents an extension of prior
findings on amyloid accumulators. That higher baseline amyloid bur-
den predicts faster accumulation is known from PET3,5,27 and CSF
studies.28,29 APOE 𝜀4 was a significant predictor of membership to
the faster accumulation group. The modulating effect of APOE 𝜀4 on
rate of amyloid accumulation extends our group’s previous analysis
on a smaller proportion of the BLSA cohort,30 which showed that
APOE 𝜀4 associates with higher likelihood for and earlier onset of
cortical amyloid accumulation. It is also consistent with established
meta-analytic evidence for earlier and faster amyloid deposition in
individuals with this genotype.31 Studies reporting intra-individual
AD biomarker changes as a function of APOE 𝜀4 status, however,
have been conflicting. For example, although APOE 𝜀4 was associated
with amyloid accumulation among initially cognitively healthy elderly
individuals,32 reports from the ADNI study did find this using either
amyloid PET5 or CSF.29 The difference could lie in the longer duration
of follow-up and more frequent measurement in the positive studies
versus the ADNI analyses.
Episodic memory was a significant predictor in the CSF but not the
PET amyloid models. The CSF result follows evidence that amyloid
accumulation associates with amnestic but not executive function or
processing-speed deficits.33,34 A potential reason for the lack of effect
in the PET analysis is that the BLSA sample was significantly older than
BIOCARD (mean ages 76 vs 58). Thus it is possible that the effect of
amyloid accumulation on cognition is particularly impactful at younger
ages, supporting further the need for interventions to be deployed
early in the lifespan.
Distinct classes of p-Tau accumulation were also identified. Faster
accumulation associatedwith higher baseline p-Tau thus replicated the
relationship observed for amyloid. The result is consistent with studies
showing that baseline p-Tau levels predict progression to impairment
in initially cognitively normal individuals.35 Taken together the amyloid
and tau accumulator findings demonstrate the potential for identifying
those at risk for faster progressionwhile still in the preclinical stages of
the disease.
The non-linear relationships between AD biomarkers and age we
describe represent an important extension of the existing literature. A
meta-analysis of PET studies has already demonstrated that a signifi-
cant increase in amyloid deposition begins at the age of 50.31 However,
cross-sectional nature of the observations limit the conclusions that
can be drawn about individual trajectories. Here, using a sample con-
sisting of CSF and PET measurements spanning over 20 and 14 years,
respectively, we are able to show that even in those with no APOE
𝜀4 alleles, a sharp inflection in the accumulation of both amyloid and
p-Tau occurs, although at a later point in life relative to those with
APOE 𝜀4 alleles (on average 8 years later). The design of the cur-
rent analysis allowed us to compare the time point of amyloid
change between PET and CSF, revealing that detectable change occurs
10 years earlier in CSF relative to PET. This result is consistent
with established models of sequential biomarker change in AD, which
argues that CSF biomarkers are the first to become abnormal.36 The
importance of considering non-linear effects is highlighted by one
other study in longitudinal CSF that found both elevations and reduc-
tions in amyloid to associate with an increase in p-Tau/tau.9
Our CSF finding of amyloid and p-tau beginning their significant
change from baseline at approximately the same age (57 for amy-
loid and 55 for p-tau) is potentially important, as it has relevance
to the hypothesis that widespread amyloid burden is required to
trigger excessive tau hyperphosphorylation.36 The extent to which
this sequential turn of events can be evidenced in practice, however,
has been hampered by the lack of appropriate middle-age sampling
as well as within-subject longitudinal data as highlighted by the
authors.36 An alternative view, based on pathological studies describ-
ing tau pathology at a younger age than amyloid plaques,7,37 is that
hyperphosphorylation and amyloid plaque formation are indepen-
dently occurring pathophysiological processes that share a common
etiology.38 Our findings of near-simultaneous change in amyloid and
tau in a large database of intra-individual longitudinal CSF measure-
ments support the view that tau phosphorylation accelerates at the
very least soon after amyloid deposition has begun. That relatively
modest amounts of amyloid deposition can have deleterious effects
is supported by evidence that subthreshold amyloid accumulation
in the negative amyloid range associates with worsening episodic
memory ability.5 Even prior to cognitive change, hypometabolism and
atrophy have been shown to significantly accelerate more than 20 and
17 years, respectively, before participants reach amyloid positivity,3
thus arguing against the requirement for widespread amyloid to
trigger the pathophysiological cascade.
4.1 Limitations
Although theamyloid latent class result performedwell, the confidence
in thep-Tauaccumulators latent classmodel is lower. This highlights the
well-recognized challenges to predicting who will develop tau pathol-
ogy. Given that the best predictive power for future impairment comes
from combining amyloid and tau measures in a ratio,29,35,39 it may be
that combined amyloid/p-tau progression models will be required to
identify those at risk of converting clinically. The non-linear analysis
should also be treatedwith caution given that individuals have an aver-
age of less than threemeasurements per person.
A further limitation is that we have used the term “accumulator”
to account for both those who increase in the strength of their PET
signal as well as progressively reduce their AD biomarker concentra-
tion levels in their CSF. This is likely an oversimplification as of the two
only PET gives direct evidence of signal accumulation. In contrast, CSF
metabolite levels are the result of a much more dynamic system, the
balance between production and clearance40 as well as preanalytical
factors that have been shown to introduce variability.41 Therefore, the
term “accumulator” should be used with caution when CSF biomarker
progression is concerned.
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5 CONCLUSIONS
The current analysis demonstrates the existence of distinct classes of
amyloid and p-Tau accumulators. Given the accumulating evidence for
pathological effects of subthreshold amyloid, this result underscores
the importance of identifying individuals who are on the path to amy-
loidpositivity and/or rapid tauphosphorylation. Thecurrently available
predictive models of these subclasses are modest, which emphasizes
the need for further work on developing biomarkers that are phase-
specific, that is, more relevant to the preclinical stage of the disease.
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